Abstract:AIM:To investigate the impact of minimum tacrolimus (TAC) on new-onset diabetes mellitus (NODM) after liver transplantation (LT). METHODS:We retrospectively analyzed the data of 973 liver transplant recipients between March 1999 and September 2014 in West China Hospital Liver Transplantation Center. Following the exclusion of ineligible recipients, 528 recipients with a TAC-dominant regimen were included in our study. We calculated and determined the mean trough concentration of TAC (cTAC) in the year of diabetes diagnosis in NODM recipients or in the last year of the follow-up in non-NODM recipients. A cutoff of mean cTAC value for predicting NODM 6 mo after LT was identified using a receptor operating characteristic curve. TAC-related complications after LT was evaluated by χ(2) test, and the overall and allograft survival was evaluated using the Kaplan-Meier method. Risk factors for NODM after LT were examined by univariate and multivariate Cox regression. RESULTS:Of the 528 transplant recipients, 131 (24.8%) developed NODM after 6 mo after LT, and the cumulative incidence of NODM progressively increased. The mean cTAC of NODM group recipients was significantly higher than that of recipients in the non-NODM group (7.66 ± 3.41 ng/mL vs 4.47 ± 2.22 ng/mL, P < 0.05). Furthermore, NODM group recipients had lower 1-, 5-, 10-year overall survival rates (86.7%, 71.3%, and 61.1% vs 94.7%, 86.1%, and 83.7%, P < 0.05) and allograft survival rates (92.8%, 84.6%, and 75.7% vs 96.1%, 91%, and 86.1%, P < 0.05) than the others. The best cutoff of mean cTAC for predicting NODM was 5.89 ng/mL after 6 mo after LT. Multivariate analysis showed that old age at the time of LT (> 50 years), hypertension pre-LT, and high mean cTAC (≥ 5.89 ng/mL) after 6 mo after LT were independent risk factors for developing NODM. Concurrently, recipients with a low cTAC (< 5.89 ng/mL) were less likely to become obese (21.3% vs 30.2%, P < 0.05) or to develop dyslipidemia (27.5% vs 44.8%, P <0.05), chronic kidney dysfunction (14.6% vs 22.7%, P < 0.05), and moderate to severe infection (24.7% vs 33.1%, P < 0.05) after LT than recipients in the high mean cTAC group. However, the two groups showed no significant difference in the incidence of acute and chronic rejection, hypertension, cardiovascular events and new-onset malignancy. CONCLUSION:A minimal TAC regimen can decrease the risk of long-term NODM after LT. Maintaining a cTAC value below 5.89 ng/mL after LT is safe and beneficial.

Characteristics of Recipients with Complete Immunosuppressant Withdrawal after Adult Liver Transplantation

Lower Tacrolimus Trough Levels in the Late Period after Living Donor Liver Transplantation Contribute to Improvements in Long-Term Clinical Outcomes.

A High Frequency of CD8+CD28- T-suppressor Cells Contributes to Maintaining Stable Graft Function and Reducing Immunosuppressant Dosage after Liver Transplantation

Immunosuppression-related complications in liver transplant recipients over 5 years survival time:experience from a single center

Higher Tacrolimus Blood Concentration is Related to Increased Risk of Post-Transplantation Diabetes Mellitus after Living Donor Liver Transplantation

Clinical Study of Early Steroid Withdrawal after Liver Transplantation

Application value of Tacrolimus sustained-release capsules in patients after liver transplantation

Effect of Low-Dose Tacrolimus with Mycophenolate Mofetil on Renal Function Following Liver Transplantation.

Higher Tacrolimus Blood Concentration is Related to Hyperlipidemia in Living Donor Liver Transplantation Recipients

A Retrospective Analysis of the Safety and Efficacy of Low Dose Tacrolimus (fk506) for Living Donor Liver Transplant Recipients

A follow-up report on liver transplantation recipients treated with tacrolimus and survived for ten or more years

Minimizing Tacrolimus Decreases the Risk of New-Onset Diabetes Mellitus after Liver Transplantation

Impact of immunosuppression level on liver allograft fibrosis after pediatric liver transplantation: a retrospective cohort study

Retrospective analysis of immunosuppression drug withdrawal after liver transplantation

Adequate cumulative exposure to tacrolimus and low tacrolimus variability decrease the incidence of biliary complications after liver transplantation

Individualized immunosuppressive regimens for long-term surviving liver transplant recipients with chronic renal dysfunction

[Long-Term Complications after Liver Transplantation].

Immunosuppressive Activity of Serum Taken from a Liver Transplant Recipient after Withdrawal of Immunosuppressants

The Morbidity and Survival of 196 Consecutive Cases Undergoing Liver Transplantation in a Single Center in Mainland China: Ten-Year Experience.

[The Diagnosis and Treatment of Late Acute Rejection after Adult Orthotopic Liver Transplantation].

Role of Steroid Minimization in the Tacrolimus-Based Immunosuppressive Regimen for Liver Transplant Recipients: a Systematic Review and Meta-Analysis of Prospective Randomized Controlled Trials.